The Role of Regulatory T Cells in Cancer

키워드

참고문헌 (201)

1. Block MS, "The tumor", immune interface:clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion, 2009, pp.5, 29~40
2. Zitvogel L, "Cancer despite immunosurveillance:immunoselectionand immunosubversion", Nat Rev Immunol, 6, pp.715~727 (2006)
3. Dougan M, "Immune therapy for cancer", Ann Rev Immunol, 27, pp.83~117 (2009)
4. Fujimoto S, "Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts", J Immunol, 116, pp.800~806 (1976)
5. Ha TY, "Potentiation of anti-tumor immunity by modulation of suppressor T cells. II. Regression of tumor by modulation of suppressor T cells", Korean J Immunol, 17, pp.101~118 (1995)
6. Gershon RK, "Suppressor T cells", J Immunol, 108, pp.586~590 (1972)
7. Gershon RK, "Infectious immunological tolerance", Immunol, 21, pp.903~914 (1971)
8. Durkin HG, "Thymus and tolerance in Is regulation the major function of the thymus?", Immunol Rev, 182, pp.33~57 (2001)
9. Waksman BH, "Tolerance, the thymus, and suppressor T cells", Clin Exp Immunol, 28, pp.363~374 (1977)
10. Sakaguchi S, "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanisms of self-tolerance causes various autoimmune diseases", J Immunol, 155, pp.1151~1164 (1995)
11. Sakaguchi S, "Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune response", Ann Rev Immunol, 22, pp.531~562 (2004)
12. Zou W, "Regulatory T cells, tumor immunity and immunotherapy", Nat Rev Immunol, 6, pp.295~307 (2006)
13. Beyer M, "Regulatory T cells in cancer", Blood, 108, pp.804~811 (2006)
14. Curiel TJ, "Tregs and rethinking cancer immunotherapy", J Clin Invest, 117, pp.1167~1174 (2007)
15. Yang ZZ, "The role of Treg cells in the cancer immunological response", Am J Immunol, 5, pp.17~28 (2009)
16. Shen LS, "CD4+CD25+CD127(low", ?)regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression, 2009, pp.131, 109~118
17. Ke X, "Roles of CD4+CD25(high)FOXP3 Tregs in lymphomas and tumors are complex", Front Biosci, 13, pp.3986~4001 (2008)
18. Schabowsky RH, "Targeting CD4+CD25+Foxp3+ regulatory T-cells for the augmentation of cancer immunotherapy", Curr Opin Invest Drugs, 8, pp.1002~1008 (2007)
19. Jarnicki AG, "Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics", J Immunol, 180, pp.3797~3806 (2008)
20. Nicholaou T, "Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients wih advanced malignant melanoma", Clin Cancer REs, 15, pp.2166~2173 (2009)
21. Curiel TJ, "Regulatory T cells and treatment of cancer", Curr Opin Immunol, 20, pp.241~246 (2008)
22. Leon K, "How regulatory CD25+CD4+ T cells impinge on tumor immunobiology:The differential response of tumors to therapies", J Immunol, 179, pp.5659~5668 (2007)
23. Tokuno K, "Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer", Anticancer Res, 29, pp.1527~1532 (2009)
24. Carreras J, "High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma", J Clin Oncol, 27, pp.1470~1476 (2009)
25. Liu Z, "Tumor regulatory T cells potently abrogate antitimor immunity", J Immunol, 182, pp.6160~6167 (2009)
26. Salama P, "Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer", J Clin Oncol, 27, pp.186~192 (2009)
27. Wang RF, "Regulatory T cells and innate immune regulation in tumor immunity", Springer Semin Imunopathol, 28, pp.17~23 (2006)
28. Fietta AM, "Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing raidofrequency thermal ablation for lung cancer", Human Immunol, 70, pp.477~486 (2009)
29. Morse MA, "Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines", Blood, 112, pp.610~618 (2008)
30. Ruter J, "Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines", Front Biosci, 14, pp.1761~1770 (2009)
31. Mailloux AW, "NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment", J Immunol, 182, pp.2753~2765 (2009)
32. Liyanage UK, "Increase prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma", J Immunother, 29, pp.416~424 (2006)
33. Lizee G, "Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms", Clin Cancer Res, 12, pp.4794~4803 (2006)
34. Lin YC, "Effector", memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity, 2009, pp.182, 6095~6104
35. van der Viliet HJ, "Exploiting regulatory T-cell populations for the imunotherapy of cancer", J Immunother, 30, pp.591~595 (2007)
36. Liyanage UK, "Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma", J Immunol, 169, pp.2756~2761 (2002)
37. Ormandy LA, "Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma", Cancer Res, 65, pp.2457~2464 (2005)
38. Matkowski R, "The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer", Anticancer Res, 29, pp.2445~2451 (2009)
39. Schreiber TH, "The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors", Cancer Epidemiol Biromarker Prev, 16, pp.1931~1934 (2007)
40. Siddiqui SA, "Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma", Clin Cancer Res, 13, pp.2075~2081 (2007)
41. Heimberger AB, "Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas", Clin Cancer Res, 14, pp.5166~5172 (2008)
42. Nishikawa H, "CD4＋CD25＋ regulatory Tcells control the induction of antigen-specific CD4＋ helper T cell responses in cancer patients", Blood, 106, pp.1008~1011 (2005)
43. Mahnke K, "kinetics of Treg depletion and alterations in immune functions in vivo and in vitro", Int J Cancer, 120, pp.2723~2733 (2007)
44. Juang CM, "Potential target in anticancer immunotherapy", Taiwan J Obstet Gynecol, 46, pp.215~221 (2007)
45. Shevach EM, "Mechanisms of Toxp3+ T regulatory cell-medicated suppression", Immunity, 30, pp.636~645 (2009)
46. Ha TY, "The role of suppressor T cells in mycobacterial infection", Korean Lepr Bull, 41, pp.3~25 (2008)
47. 하대유, "Regulatory T Cell Therapy for Autoimmune Disease", Immune Network, 8(4), pp.107~123 (2008), 대한면역학회
48. Ha TY, "The role of suppressor T cells in bacterial infections", KAST Rev Modern Sci & Technol, 4, pp.105~120 (2008)
49. Shevach EM, "Certified professionals: CD4+ CD25+ suppressor T cells", J Exp Med, 193, pp.F41~46 (2001)
50. Mudd PA, "Regulatory T cells and systemic lupus erythematosus", Scand J Immunol, 64, pp.211~218 (2006)
51. Ha TY, "Role of the thymus in tolerance .X. Suppressor activity of antigen-stimulated rat thymocytes transferred to normal recipients", J Immunol, 110, pp.1290~1299 (1973)
52. Ha TY, "Thymic suppressor cell. I. Separation of subpopulation with suppressor activity", J Exp Med, 139, pp.13~23 (1974)
53. Ha TY, "The thymic suppressor cell. II. Metabolic requirement of suppressor activity", Immunol Commun, 3, pp.351~359 (1974)
54. Riley JL, "Human T regulatory cell therapy: take a billion or so and call me in the morning", Immunity, 30, pp.656~665 (2009)
55. Mabarrack NH, "Recent thymic origin, differentiation, and turnover of regulatory T cells", J Leukoc Biol, 84, pp.1287~1297 (2008)
56. Ziegler SF, "FOXP3: of mice and men", Ann Rev Immunol, 24, pp.209~226 (2006)
57. Miyara M, "Functional delineation and differentiation dynamics of human CD4+ T cells expressing the Foxp3 transcription factor", Immuity, 30, pp.899~911 (2009)
58. Qin FX, "Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host", Cell Mol Immunol, 6, pp.3~13 (2009)
59. Huen J, "Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?", Nat Rev Immunol, 9, pp.83~89 (2009)
60. Fontenot JD, "Regulatory T cell lineage specification by the forkhead transcription factor foxp3", Immunity, 22, pp.329~341 (2005)
61. Walker MR, "Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells", J Clin Invest, 112, pp.1437~1443 (2003)
62. Hubert P, "The cross-talk between dendritic and regulatory T cells: good or evil?", J Leukoc Biol, 82, pp.781~794 (2007)
63. Toda A, "Development and function of naturally occurring CD4+CD25+ regulatory T cells", J Leukoc Biol, 80, pp.458~470 (2006)
64. Wang HY, "Regulatory T cells and cancer", Curr Opin Immunol, 19, pp.217~223 (2007)
65. Han Y, "CD69+ CD4+CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1", J Immunol, 182, pp.111~120 (2009)
66. Maggi E, "Thymic regulatory T cells", Autoimmun Rev, 4, pp.579~586 (2005)
67. Generali D, "Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer", Clin Cancer Res, 15, pp.1046~1051 (2009)
68. Powell DJ Jr, "Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples", J Immunother, 28, pp.403~411 (2005)
69. Beissert S, "Regulatory T cells", J Invest Dermatol, 126, pp.15~24 (2006)
70. Brahmachari S, "Suppression of regulatory T cells by? IL-12p40 homodimer via nitric oxide", J Immunol, 183, pp.2045~2058 (2009)
71. Wan YY, "Yin-Yang functions of transforming growth factor-beta and T regulatory cells in immune regulation", Immunol Rev, 220, pp.199~213 (2007)
72. Curotto de Lafaille MA, "Natural and adaptive Foxp3+ regulatory T cells: More of the same or a division of labor?", Immunity, 30, pp.626~635 (2009)
73. Zhou X, "Plasticity of CD4+Foxp3+ T cells", Curr Opin Immunol, 21, pp.281~285 (2009)
74. Valzasina B, "Tumor-induced expansion of regulatory? T cells by conversion of CD4+CD25-lymphocytes is thymus and proliferation independent", Cancer Res, 66, pp.4488~4895 (2006)
75. Liu VC, "Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta", J Immunol, 178, pp.2883~2892 (2007)
76. Viel CT, "Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice", Ann Surg Oncol, 13, pp.1252~1258 (2006)
77. Antony PA, "CD8+ T cell immunity against a tumor", self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells, 2005, pp.174, 2591~2601
78. Linehan DC, "CD25+CD4+ regulatory T-cells in cancer", Immunol Res, 32, pp.155~168 (2005)
79. Hiur T, "Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression", J Immunol, 175, pp.5058~5066 (2005)
80. Hontsu S, "Visualization of naturally occurring Foxp3+ regulatory T cells in normal and tumor-bearing mice", Int Immunopharmacol, 4, pp.1785~1793 (2004)
81. Tien AH, "Altered immunity accompanies disease progression in a mouse model of prostate dysplasia", Cancer Res, 65, pp.2947~2955 (2005)
82. Liu JY, "The changes of CD4+CD25+", CD4+proportion in spleen of tumor-bearing BALB, J Transl Med, pp.2005, 3[DOI]
83. Golgher D, "Depletion of CD25+regulatory cells uncovers immune responses to shared murine tumor rejection antigens", Eur J Immunol, 32, pp.3267~3275 (2002)
84. Ghiringhelli F, "CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative", Eur J Immunol, 34, pp.336~344 (2004)
85. El Andaloussi A, "Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors", J Neurosurg, 105, pp.430~437 (2006)
86. Sutmuller RP, "Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses", J Exp Med, 194, pp.823~832 (2001)
87. Sharma S, "Tumor cyclooxygenase-2", prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer, 2005, pp.65, 5211~5220
88. Turk MJ, "Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells", J Exp Med, 200, pp.771~782 (2004)
89. Lutsiak ME, "Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells", J Immunol, 180, pp.5871~5881 (2008)
90. Mizukami Y, "CCL17 and CCL22 chemokines within tumor environment are related to accumulation of Toxp3+regulatory T cells in gastric cancer", Int J Cancer, 122, pp.2286~2293 (2008)
91. Curiel TJ, "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival", Nat Med, 10, pp.942~949 (2004)
92. Grauer OM, "CD4+Foxp3+regulatory T cells gradually accumulate in glioma during tumor growth and efficiently suppress antiglioma immue responses in vivo", Int J Cancer, 121, pp.95~105 (2007)
93. Shimizu J, "Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity", J Immunol, 163, pp.5211~ (1999), 5218
94. Tanaka H, "Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes", J Immunother, 25, pp.207~217 (2002)
95. Prasad SJ, "Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+regulatory T cells", J Immunol, 174, pp.90~98 (2005)
96. Van Meirvenne S, "In vivo depletion of CD4+CD25+regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells", Mol Ther, 12, pp.922~932 (2005)
97. Onizuka S, "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody", Cancer Res, 59, pp.3128~3133 (1999)
98. Fu T, "Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A", J mice, 2000, pp.87, 680~687
99. Jones E, "Deletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice", Cancer Immun, 2, pp.1~ (2002)
100. Casares N, "CD4+", CD25+regulatory cells inhibit activation of tumorprimed CD4+Tcells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination, 2003, pp.171, 5931~5939
101. Yu P, "Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors", J Exp Med, 201, pp.779~791 (2005)
102. Quezada SA, "Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma", J Exp Med, 205, pp.2125~2138 (2008)
103. Wrzesinski C, "Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells", J Clin Invest, 117, pp.492~501 (2007)
104. Heier I, "Depletion of CD4+CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma", Clin Exp Immunol, 152, pp.381~387 (2008)
105. Lee CH, "Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor response", Clin Cancer Res, 15, pp.2756~2766 (2009)
106. pyrene-induced forestomach carcinoma, "World J Gastroenterol", 2008, 5797~5809
107. Tan MC, "Distribution of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer", J Immunol, 182, pp.1746~1755 (2009)
108. Wing K, "CTLA-4 control over Foxp3+ regulatory T cell function", Science, 322, pp.271~275 (2008)
109. Woo EY, "regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer", Cancer Res, 61, pp.4766~4772 (2001)
110. Woo EY, "Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation", J Immunol, 168, pp.4272~4276 (2002)
111. Orentas RJ, "Suppression of anti-cancer immunity by regulatory T cells: back to the future", Seminar Cancer Biol, 16, pp.137~149 (2006)
112. Danesse S, "The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity", Curr Med Chem, 14, pp.649~666 (2007)
113. Barnett BG, "Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol 622;255-260, 2008 Daniel BJ, Coukos G, Zou W, Curiel TJ: Regulatory T cells:a new frontier in cancer immunotherapy", Adv Exp Med Biol, 622, pp.255~260 (2008)
114. Sasada T, "CD4+CD25+ regulatory Tcells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression", Cancer, 98, pp.1089~1099 (2003)
115. Kawaida H, "Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer", J Surg Res, 124, pp.151~157 (2005)
116. Kono K, "CD4(+) CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers", Cancer Immunol Immunother, 55, pp.1064~1071 (2006)
117. Ichihara F, "Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers", Clin Cancer Res, 9, pp.4404~4408 (2003)
118. Xu H, "CD4+CD25+ regulatory T cells in patients with advanced gastrointestinal cancer treated with chemotherapy", Onkologie, 32, pp.246~252 (2009)
119. Gobert M, "Regulatory T cells recruited through CCL22", CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, 2009, pp.69, 2000~2009
120. Qin XJ, "CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion", Clin Cancer Res, 15, pp.2231~2237 (2009)
121. Wieczorek G, "Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue", Cancer Res, 69, pp.599~608 (2009)
122. Schaefer C, "Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer", Br J Cancer, 92, pp.913~920 (2005)
123. Strauss L, "The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck", Clin Cancer Res, 13, pp.6301~6311 (2007)
124. Gao Q, "Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection", J Clin Oncol, 25, pp.2586~2593 (2007)
125. Kobayashi N, "FOXP3+ regulatory T cells affect the development and progression of hepatocarinogenesis", Clin Cancer Res, 13, pp.902~911 (2007)
126. Gray CP, "Association of increased levels of heavy-chain ferritin with increased CD4+CD25+regulatory T-cell levels in patients with melanoma", Clin Cancer Res, 9, pp.2551~2559 (2003)
127. Viguier M, "Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells", J Immunol, 173, pp.1444~1453 (2004)
128. Mao C, "Increased CD4+CD25+FOXP3+regulatory T cells in cancer patients from conversion of CD4+CD25-T cells through tumor-derived factors", Onkologie, 31, pp.243~248 (2008)
129. Powell DP Jr, "Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo", J Immunol, 179, pp.4919~4928 (2007)
130. Javia LR, "CD4+CD25+suppressor lymphocytes in the circulation of patients immunized against melanoma antigens", J Immunother, 26, pp.85~93 (2003)
131. McCarter MD, "Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients", Ann Surg Oncol, 14, pp.2854~2860 (2007)
132. Vence L, "Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma", Proc Natl Acad Sci USA, 104, pp.20884~20889 (2007)
133. Pallandre JR, "Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus- host disease and antitumor immunity", J Immunol, 179, pp.7593~7604 (2007)
134. Wang W, "Effects of high-dose IFNα2b on regional lymph node metastases of human melanoma: Modulation of STAT5, FOXP3, and IL-17", Clin Cancer Res, 14, pp.8314~8320 (2008)
135. Ahmadzadeh M, "IL-2 administration increases CD4+CD25(hi) Foxp3+regulatory T cells in cancer patients", Blood, 107, pp.2409~2414 (2006)
136. Hiraoka N, "Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions", Clin Cancer Res, 12, pp.5423~5434 (2006)
137. Miller AM, "CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients", J Immunol, 177, pp.7398~7405 (2006)
138. Rozkova D, "FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer", Clin Immunol, 131, pp.1~10 (2009)
139. Jensen HK, "Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma", Clin Cancer Res, 15, pp.1052~1058 (2009)
140. Li, X, "Proportion of CD4CD25 regulatory T cell is increased in the patients with ovarian carcinoma", Cancer Invest, 23, pp.399~403 (2005)
141. Leffers N, "Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesion of advanced stage ovarian cancer", Cancer Immunol Immunother, 58, pp.449~459 (2009)
142. Fattorossi A, "Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma", Cancer, 100, pp.1418~1428 (2004)
143. Fattorossi A, "Lymphocyte compostion of tumor draining lymphnodes from cervical and endometrial cancer patients", Gynecol Oncol, 92, pp.106~115 (2004)
144. Wolf AM, "Increase of regulatory T cells in the peripheral blood of cancer patients", Clin Cancer Res, 9, pp.606~612 (2003)
145. Bates GJ, "Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and hose at risk of late relapse", J Clin Oncol, 24, pp.5373~5380 (2006)
146. Ohara M, "Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer", Cancer Immunol Iimmunother, 58, pp.441~447 (2009)
147. Hueman MT, "Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2", neu peptide (E75) and GM-CSF vaccine, 2006, pp.98, 17~29
148. Merio A, "FOXP3 expression and overall survival in breast cancer", J Clin Oncol, 27, pp.1746~1752 (2009)
149. Lehe C, "The Wilms'tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy", Cancer Res, 68, pp.6350~6359 (2008)
150. Beyer M, "In vivo peripheral expansion of naive CD4+CD25highFoxp3+ regulatory T cells in patients with multiple myeloma", Blood, 107, pp.3940~3949 (2006)
151. Prabhala RH, "Dysfuntional T regulatory cells in multiple myeloma", Blood, 107, pp.301~304 (2006)
152. Karube K, "Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia", lymphoma cells, 2004, pp.126, 81~84
153. Yano H, "Regulatory T-cell function of adult T-cell leukemia", lymphoma cells, 2007, pp.120, 2052~2057
154. Motta M, "Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia", Leukemia, 19, pp.1788~1793 (2005)
155. Beyer M, "Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine", Blood, 106, pp.2018~2025 (2005)
156. Wang X, "Increased population of CD4+CD25high,regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients", Eur J Haematol, 75, pp.468~476 (2005)
157. Szczepanski MJ, "Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia", Clin Cancer Res, 15, pp.3325~3332 (2009)
158. Carreras J, "High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma", Blood, 108, pp.2957~2964 (2006)
159. Yang ZZ, "Intratumoral CD4+CD25+regulatory T-cell-mediated suppression of infiltrating CD4+T-cells in B-cell non-Hodgkin lymphoma", Blood, 107, pp.3639~3646 (2006)
160. Yang ZZ, "Attenuation of CD8(+) T-cell function by CD4(+)CD25(+)regulatory T cells in B-cell non-Hodgkin's lymphoma", Cancer Res, 66, pp.10145~10152 (2006)
161. Marshall NA, "Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma", Blood, 103, pp.1755~1762 (2004)
162. Alvaro T, "Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells", Clin Cancer Res, 11, pp.1467~1473 (2005)
163. Baecher-Allan C, "Human CD4+CD25+ regulatory T cells", Semin Immunol, 16, pp.89~98 (2004)
164. Kosmaczewska A, "The significance of Treg cells in defective tumor immunity", Arch Immunol Ther EXp, 56, pp.181~191 (2008)
165. Foss FM, "DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma", Clin Lymphoma, 1, pp.110~116 (2000)
166. Wong BY, "Denileukin diftitox as novel targeted therapy for lymphoid malignancies", Cancer Invest, 25, pp.495~501 (2007)
167. Chin KM, "Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox", Clin Lymphoma Myeloma, 7, pp.199~204 (2006)
168. Dannull J, "Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells", J Clin Invest, 115, pp.3623~3633 (2005)
169. Foss F, "Clinical experience with denileukin diftitox (ONTAK)", Semin Oncol, 33, pp.S11~16 (2006)
170. Litzinger MT, "IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity", Blood, 110, pp.3192~3201 (2007)
171. Powell DJ Jr, "Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration", J Immunother, 31, pp.189~198 (2008)
172. Olkhanud PB, "Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells", Cancer Res, 69, pp.5996~6004 (2009)
173. Curtin JF, "Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials", PLoS One, 3, pp.e1983~ (2008)
174. Yang XF, "Factors regulating apoptosis and homeostasis of CD4+ CD25(high) FOXP3+ regulatory T cells are new therapeutic targets", Front Biosci, 13, pp.1472~1499 (2008)
175. Huang S, "Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications", Clin Cancer Res, 13, pp.1362~1366 (2007)
176. Ling X, "Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice", Cancer Res, 65, pp.2532~2536 (2005)
177. Caramalho I, "Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide", J Exp Med, 197, pp.403~411 (2003)
178. Peng G, "Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function", Science, 309, pp.1380~1384 (2005)
179. Wang RF, "Regulatory T cells and Toll-like receptors in tumor immunity", Semin Immunol, 18, pp.136~142 (2006)
180. Chakraborty NG, "Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma", Hum Immunol, 65, pp.794~802 (2004)
181. Nair S, "Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity", Cancer Res, 67, pp.371~380 (2007)
182. Francois V, "The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells", Cnacer Res, 69, pp.4335~4345 (2009)
183. Jacob JB, "Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity", J Immunol, 182, pp.5873~5881 (2009)
184. Hiraoka N, "Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions", Clin Cancer Res, 12, pp.5423~5434 (2006)
185. Shevach EM, "Fatal attraction: tumors beckon regulatory T cells", Nat Med, 10, pp.900~901 (2004)
186. Lu H, "FOXP3 expression and prognosis: role of both the tumor and T cells", J Clin Oncol, 27, pp.1735~1736 (2009)
187. Kryczek I, "FOXP3 defines regulatory T cells in human tumor and autoimmune disease", Cancer Res, 69, pp.3995~4000 (2009)
188. Badoual C, "Revisiting the prognostic value of regulatory T cells in patients with cancer", J Clin Oncol, 27, pp.e5~6 (2009)
189. Badoual C, "Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers", Clin Cancer Res, 12, pp.465~72 (2006)
190. Wolf D, "Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients", Cancer Immunol Immunother, 55, pp.1198~1208 (2006)
191. Elpek KG, "CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model", J Immunol, 178, pp.6840~6648 (2007)
192. Shafer-Weaver KA, "Cutting Edge: tumor-spe cific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells", J Immunol, 183, pp.4848~4852 (2009)
193. Petrausch U, "Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity", J Immunol, 183, pp.3682~3689 (2009)
194. Miyara M, "Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor", Immunity, 30, pp.899~911 (2009)
195. Ashley CW, "Cutting Edge: responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B", J Immunol, 183, pp.4843~4847 (2009)
196. Lu LF, "Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein", Immunity, 30, pp.80~91 (2009)
197. Lodish HF, "Micromanagement of the immune system by microRNAs", Nat Rev Immunol, 8, pp.120~130 (2008)
198. Xiao C, "MicroRNA control in the immune system:basic principles", Cell, 136, pp.26~36 (2009)
199. Lindsay MA, "microRNAs and the immune response", Trends Immunol, 29, pp.343~351 (2008)
200. Kohlhaas S, "Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells", J Immunol, 182, pp.2578~2582 (2009)
201. Ventura A, "MicroRNAs and cancer: short RNAs go a long way", Cell, 136, pp.586~591 (2009)

관련 논문AI추천